ADMA Biologics (ADMA) Scheduled to Post Earnings on Thursday

ADMA Biologics (NASDAQ:ADMA) will post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect ADMA Biologics to post earnings of $0.05 per share for the quarter. ADMA Biologics has set its FY 2024 guidance at EPS and its FY 2025 guidance at EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. The firm had revenue of $73.90 million for the quarter, compared to the consensus estimate of $73.50 million. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. On average, analysts expect ADMA Biologics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Stock Performance

Shares of NASDAQ:ADMA opened at $6.91 on Wednesday. The company has a market cap of $1.58 billion, a PE ratio of -53.15 and a beta of 0.43. The company’s 50-day moving average price is $6.27 and its 200 day moving average price is $5.06. ADMA Biologics has a fifty-two week low of $3.06 and a fifty-two week high of $6.97. The company has a quick ratio of 1.69, a current ratio of 5.16 and a debt-to-equity ratio of 1.04.

Analysts Set New Price Targets

ADMA has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $7.50 price objective (up from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. Mizuho raised their target price on shares of ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Cantor Fitzgerald raised their target price on shares of ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $7.88.

Insider Transactions at ADMA Biologics

In other news, Director Steve Elms sold 183,008 shares of ADMA Biologics stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $6.01, for a total value of $1,099,878.08. Following the transaction, the director now owns 2,577,387 shares of the company’s stock, valued at approximately $15,490,095.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 639,895 shares of company stock valued at $3,927,169 in the last quarter. Insiders own 3.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.